Titre :

Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the acute leukaemia working party of the ebmt

Auteur(s) :

Gilleece, Maria H. [Auteur]
Labopin, Myriam [Auteur]
Savani, Bipin N. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Socie, Gerard [Auteur]
Gedde-Dahl, Tobias [Auteur]
Blaise, Didier [Auteur]
Centre de Recherche en Cancérologie de Marseille [CRCM]
Byrne, Jennifer L. [Auteur]
Craddock, Charles [Auteur]
Cornelissen, Jan J. [Auteur]
Arcese, William [Auteur]
Forcade, Edouard [Auteur]
Crawley, Charles [Auteur]
Polge, Emmanuelle [Auteur]
Mohty, Mohamad [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Nagler, Arnon [Auteur]

Titre de la revue :

Leukemia

Nom court de la revue :

Leukemia

Numéro :

34

Pagination :

87–99

Date de publication :

2020-01

ISSN :

1476-5551

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Allogeneic haemopoietic cell transplant (allo-HCT) may be curative in acute myeloid leukaemia (AML) in second complete remission (CR2) but the impact of reduced intensity (RIC) versus myeloablative conditioning (MAC) is ...
Lire la suite >Allogeneic haemopoietic cell transplant (allo-HCT) may be curative in acute myeloid leukaemia (AML) in second complete remission (CR2) but the impact of reduced intensity (RIC) versus myeloablative conditioning (MAC) is uncertain. The Acute Leukaemia Working Party of the European Society for Blood and Bone Marrow Transplantation Registry studied an AML CR2 cohort characterised by age ≥ 18 years, first allo-HCT 2007-2016, available cytogenetic profile at diagnosis, donors who were matched family, volunteer unrelated with HLA antigen match 10/10 or 9/10 or haplo-identical. The 1879 eligible patients included 1010 (54%) MAC allo-HCT recipients. In patients <50 years (y), two year outcomes for MAC vs RIC allo-HCT were equivalent with leukaemia-free survival (LFS) 54% for each, overall survival (OS), 61% vs 62%, non-relapse mortality (NRM) 18% vs 15% and graft versus host disease relapse-free survival (GRFS) 38% vs 42%. In patients ≥50 y, 2 y outcomes for MAC vs RIC allo-HCT were equivalent for LFS 52% vs 49%, OS 58% vs 55% and GRFS 42.4% vs 36%. However, NRM was significantly inferior after MAC allo-HCT, 27% vs 19% (P = 0.01) despite worse cGVHD after RIC-allo (32% vs 39%). These data support the need for ongoing prospective study of conditioning intensity and GVHD mitigation in AML.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-30T10:27:06Z
2024-01-31T13:47:52Z